Brian Mendelsohn
Company: Ajinomoto Bio-Pharma Services
Job title: Director
Seminars:
ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform 9:20 am
Site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies We report a novel method of affinity peptide mediated regiodivergent antibody functionalization that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner Both thiol-based and azide-based site-specific…Read more
day: Day Two
ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform 9:20 am
Site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies. We report a novel method of affinity peptide mediated regiodivergent antibody functionalization that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner. Both thiol-based and azide-based site-specific…Read more
Live Discussion & Question Time 10:00 am
day: Day Two